biological source
rabbit
Quality Level
conjugate
unconjugated
antibody form
IgG fraction of antiserum
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
packaging
antibody small pack of 25 μL
technique(s)
indirect ELISA: 1:1,000 using 5 × 1010 phage/ml
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Immunogen
fd 噬菌体
Application
B7786 兔抗 fd 噬菌体抗体可用于分类噬菌体展示文库（抗体、肽等），表达的蛋白与丝状噬菌体的基因 III 或基因 VIII 蛋白融合。该产品也可用于“噬菌体 ELISA”，提供重组噬菌体检测的特异性活性。当直接包被在微孔板上或作为特异性捕获的 fd 或 M13 噬菌体的一级检测抗体时，它也将起到捕获抗体的作用。
兔抗 fd 噬菌体抗体可按 1:1000 的稀释度用于 ELISA。它用于抗噬菌体免疫组化。
Biochem/physiol Actions
该抗体与 fd 噬菌体或 M13 噬菌体的噬菌体外壳蛋白特异性结合，因此当直接包被在多孔板上或作为特异性捕获 fd 或 M13 噬菌体的一级检测抗体时，可作为捕获抗体发挥作用。该抗体可用于快速分选大型噬菌体展示文库（抗体、肽等），所述表达蛋白与丝状噬菌体的基因 III 或基因 VIII 蛋白融合。该抗体可作为“噬菌体 ELISA”的检测试剂，为重组噬菌体的检测提供灵敏、特异的活性。
Physical form
0.01 M 磷酸盐缓冲盐水 (pH 7.4) 中提供的溶液，含 15 mM 叠氮化钠
Preparation Note
以 fd 噬菌体为免疫原，在家兔体内制备了抗 fd 噬菌体。分离全抗血清，然后通过离子交换色谱法进一步纯化，以提供基本上不含其他兔血清蛋白的抗血清的 IgG 组分。
Disclaimer
除非我们的产品目录或产品随附的其他公司文件中另有说明，否则我们的产品仅用于研究用途，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、体外或体内治疗用途或任何类型的人类或动物消费或应用。
Still not finding the right product?
试用我们的 产品选型工具 工具缩小选择范围
存储类别
12 - Non Combustible Liquids
法规信息
低风险生物材料
常规特殊物品
此项目有
Paola A Bignone et al.
Methods in molecular biology (Clifton, N.J.), 1357, 269-283 (2014-11-21)
The ability of human pluripotent stem cells (hPS) to both self-renew and differentiate into virtually any cell type makes them a promising source of cells for cell-based regenerative therapies. However, stem cell identity, purity, and scalability remain formidable challenges that
Anne S Knudsen et al.
Scientific reports, 12(1), 3040-3040 (2022-02-25)
The pathogenesis of malaria is associated with blood-stage infection and there is strong evidence that antibodies specific to parasite blood-stage antigens can control parasitemia. This provides a strong rational for applying blood-stage antigen components in a multivalent vaccine, as the
Daniela I Staquicini et al.
Proceedings of the National Academy of Sciences of the United States of America, 118(30) (2021-07-09)
Development of effective vaccines against coronavirus disease 2019 (COVID-19) is a global imperative. Rapid immunization of the entire human population against a widespread, continually evolving, and highly pathogenic virus is an unprecedented challenge, and different vaccine approaches are being pursued.
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| B7786-.2ML | 04061833442104 |
| B7786-.5ML | 04061833442111 |